Jitka Riedl
Seminars
Thursday 3rd December 2026
Bicycle® Radionuclide Conjugates as Theranostic Agents for Novel Tumour Targets
12:00 pm
- Bicycle® Radionuclide Conjugates (BRCs) represent a promising new oncology modality designed to combine highly precise tumour targeting with rapid tissue penetration and clearance.
- Clinical imaging data for BRCs targeting the novel cancer antigens MT1-MMP and EphA2 have successfully validated their ability to selectively deliver radioisotopes to tumours in patients.
- These early imaging conjugates can be further optimized to achieve favourable biodistribution, paving the way for advanced therapeutic development.